Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;60(1):28-31.
doi: 10.1038/s41409-024-02434-9. Epub 2024 Oct 7.

An international survey to better understand the current incidence, severity, and management of VOD/SOS

Affiliations

An international survey to better understand the current incidence, severity, and management of VOD/SOS

Marion Larue et al. Bone Marrow Transplant. 2025 Jan.

Abstract

This international questionnaire survey aimed to explore the current incidence, diagnostic policies, management, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) among healthcare providers involved in the management of these patients. A questionnaire was e-mailed to practitioners with an interest in allogeneic hematopoietic cell transplantation (allo-HCT). Of the respondents, 144 of 215 (67.0%) felt that early detection or diagnosis of VOD/SOS was difficult. Regarding diagnostic criteria, 142 (66.1%) already declared using the 2023 EBMT refined criteria. Most respondents (163/215, 75.8%) found these recent refined EBMT criteria useful for diagnosis, and 193 (89.8%) found the severity criteria easy to use. The major risk factors identified for VOD/SOS were a second allo-HCT (41.4%), pre-existing liver disease (54.9%), and prior use of antibody-drug conjugates (49.8%). Preferences for starting VOD/SOS treatment varied, with 61 (28.4%) preferring initiating therapy at a mild stage, and 122 (56.7%) preferring the moderate stage. In summary, this survey provided valuable insight into the challenges and opportunities of the identification and management of VOD/SOS. By improving current knowledge and increasing collaboration among healthcare professionals, early detection, management, and clinical outcomes for patients with this potentially serious complication can also be improved.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Ahmed Alaskar: Received honoraria/consultancy fees: Novartis, Abbvie, Janssen, Takeda, Kyowa Kirin, Gilead, Roche, Sanofi. Participated in company sponsored speakers bureau: Janssen, Kyowa Kirin, Sanofi. Michelle Kenyon: Received honoraria/consultancy fees: Jazz Pharmaceuticals, Sanofi, Roche, Mallinkrodt, Vertex. Speakers bureau: Jazz Pharmaceuticals, Sanofi, Pfizer. Ethics approval: The IACH steering committee ( www.iach.org ) approved the conduct of this survey according to standard professional practices.

References

    1. Vythoulkas D, Tsirigotis P, Griniezaki M, Konstantellos I, Lazana I. Endothelial dysfunction syndromes after allogeneic stem cell transplantation. Cancers (Basel). 2023;15:680. - DOI - PubMed - PMC
    1. Corbacioglu S, Jabbour EJ, Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant. 2019;25:1271–80. - DOI - PubMed
    1. Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, et al. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv. 2024;8:1128–36. - DOI - PubMed - PMC
    1. Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53:138–45. - DOI - PubMed
    1. Corbacioglu S, Topaloglu O, Aggarwal S. A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease/sinusoidal obstruction syndrome. Clin Drug Investig. 2022;42:465–76. - DOI - PubMed - PMC

LinkOut - more resources